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Sex Med 2Introduction: Gender incongruence defines a state in which individuals feel discrepancy between the sex
assigned at birth and their gender. Some of these people make a social transition from male to female (trans
women) or from female to male (trans men). By contrast, the word cisgender describes a person whose gender
identity is consistent with their sex assigned at birth.
Aim: To analyze the implication of the estrogen receptor a gene (ESR1) in the genetic basis of gender
incongruence.
Main Outcome Measures: Polymorphisms rs9478245, rs3138774, rs2234693, rs9340799.
Method: We carried out the analysis of 4 polymorphisms located at the promoter of the ESR1 gene
(C1 ¼ rs9478245, C2 ¼ rs3138774, C3 ¼ rs2234693, and C4 ¼ rs9340799) in a population of 273 trans
women, 226 trans men, and 537 cis gender controls. For SNP polymorphisms, the allele and genotype fre-
quencies were analyzed by c2 test. The strength of the SNP associations with gender incongruence was measured
by binary logistic regression. For the STR polymorphism, the mean number of repeats were analyzed by the
ManneWhitney U test. Measurement of linkage disequilibrium and haplotype frequencies were also performed.
Results: The C2 median repeats were shorter in the trans men population. Genotypes S/S and S/L for the C2
polymorphism were overrepresented in the trans men group (P ¼ .012 and P ¼ .003 respectively). We also
found overtransmission of the A/A genotype (C4) in the trans men population (P ¼ .017), while the A/G
genotype (C4) was subrepresented (P ¼ .009]. The analyzed polymorphisms were in linkage disequilibrium. In
the trans men population, the T(C1)-L(C2)-C(C3)-A(C4) haplotype was overrepresented (P ¼ .019) while the
T(C1)-L(C2)-C(C3)-G(C4) was subrepresented (P ¼ .005).
Conclusion: The ESR1 is associated with gender incongruence in the trans men population. Fernández R,
Delgado-Zayas E, Ramírez K, et al. Analysis of Four Polymorphisms Located at the Promoter of the
Estrogen Receptor Alpha ESR1 Gene in a Population With Gender Incongruence. Sex Med
2020;XX:XXXeXXX.
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2 Fernández et alINTRODUCTION
Gender identities are classified into “transgender” and “cis-
gender” umbrellas.1 Transgender is an adjective used to describe
a diverse group of individuals whose gender identity is different
(in varying degrees) from their sex assigned at birth. Cisgender is
used to refer to a gender identity that matches a person’s sex
assigned at birth.
When an individual applies for transgender health care, he or
she may receive a diagnosis based on fulfillment of DSM
(Diagnostic and Statistical Manual of Mental Disorders) or ICD
(International Classification of Diseases) criteria. Gender incon-
gruence2 or gender dysphoria3 criteria defines a condition in
which individuals experience a discrepancy between the sex
assigned at birth and the gender they identify with. Both terms
are more dimensional (less binary) than the previous versions,
and therefore, the diagnosis is applicable to a larger group of
individuals. Moreover, gender incongruence has been removed
from the chapter of Mental and Behavioral Disorders and moved
to a new section (Conditions Related to Sexual and Gender
Health). Nevertheless, the individuals diagnosed with gender
incongruence represent a subsample of the total spectrum of
transgender people.4
Genetic studies on transgender populations are often based on
individuals whose “experienced gender” is more binary, that is,
their identification is with “the opposite sex,” “preferred sex,” or
“the other sex” (terms currently used in the ICD-105 and DSM-
4-TR6). Many of these people make a social transition from male
to female (trans women) or from female to male (trans men),
through cross-sex hormonal treatment and subsequent physical
adaptation through surgery.7
The origin of gender incongruence seems to be multifactorial.
It might be associated with neurodevelopmental processes of the
brain.8e10 A genetic component may also be involved because
siblings of transgender individuals are more likely to be trans-
gender, compared with the general population.11,12 Most genetic
studies that analyze the genetic component of gender formation
examine the implication of genetic polymorphisms related to the
androgen receptor AR,13e18 the aromatase CYP19A1,13e18 the
estrogen receptors ER (a and b),13e19 as well as haplotypes and
the interaction effects (epistasis) between polymorphisms.20
Estrogen is produced in many regions of the brain including
the hippocampus, the cortex, the cerebellum, the hypothalamus,
and the amygdala.21 The actions of estradiol in the developing
brain are generally permanent and range from the establishment
of sexual differences (cerebral dimorphism) to generalized trophic
and neuroprotective effects.22 For this reason, given the impor-
tance of estrogens in brain dimorphism, and based on our
previous genetic studies,16,18e20,23,24 we analyzed 4 poly-
morphisms at/or flanking the promoter of the estrogen receptor
alpha ESR1 gene (Table 1), that encodes the estrogen receptor
alpha (ERa), an estrogen-activated transcription factor with a
4-fold higher affinity for estrogens than ER beta (ERb).25METHODS AND MATERIALS
Participants
The initial population was 323 trans women, 235 trans men,
and 252 cis women and 285 cis men controls, recruited through
the Gender Units of the Clínic Hospital of Barcelona (Spain) and
the Regional Universitario Hospital of Málaga (previously Carlos
Haya Hospital) (Spain) since 2010.
To obtain a homogeneous sample, avoiding stratification, we
applied the following criteria: The inclusion criteria for the
transgender groups were as follows: (1) presenting gender
incongruence according to the ICD-11, (2) gender identification
with the other gender (male or female), (3) presenting early-life
onset of gender nonconformity before or at puberty, (4) being
sexually attracted to persons with the same biological sex, (5)
having no sexual development disorder, (6) being aged between
18 and 47 years old at enrollment.
At the time of recruitment, transgender people met diagnostic
criteria according to ICD-105 and DSM-4-TR6 as assessed by
means of several interviews by experienced psychiatrists and
psychologists of both teams. To avoid stigmatization of mental
disorders, diagnosis was relabeled to gender incongruence.2 In
the current sample, changes do not interfere with the interpre-
tation of our results because transgender participants explicitly
reported feelings of belonging to the other gender and commu-
nicated the desire for hormonal and surgical gender affirmation
treatment.
Early-life onset was established by interviews evaluating
whether the gender incongruence was present in childhood
(before puberty). Sexual orientation in trans women and
trans men was recognized by asking which partner (a man, a
woman, both or neither) they would prefer or feel attraction
to, if they were completely free to choose and their body
did not interfere. Trans women and trans men underwent
endocrinological hormonal assessment to rule out hormonal
and sexual development disorders. Clinical and sociodemo-
graphic characteristics from a similar transsexual Spanish
population attended to at the same reference unit have been
described in detail elsewhere.26
The DNA samples of the cisgender group were recruited from
the biobanc generated for the Pizarra study,27 in which all par-
ticipants signed the informed consent for donation of the sam-
ples to the biobanc of the Regional Universitario Hospital of
Málaga for medical research studies. In the Pizarra study, in-
dividuals were excluded if they had been hospitalized for any
reason in the 4 weeks before the evaluation, if they were preg-
nant, or had a severe medical or psychiatric disorder. In addition,
cisgender participants were asked about any existing acute or
chronic medical conditions, and if they identified themselves as
woman, man, or other nonbinary identities. Our inclusion
criteria for cis gender subjects were as follows: (1) age between 18
and 47 years old at enrollment; (2) identification as male or
female.Sex Med 2020;-:1e11
Table 1. Description of polymorphisms and PCR conditions to amplify the polymorphic regions
Polymorphism Alias Gene Chromosome
Regulation
by Ensembl
Polymorphism
type
DNA
variation
Digestion
enzyme
Global
1000
Genomes
frequency
European
1000
Genomes
frequency
Our
study
frequency
Genotypes
resulting Primers
rs9478245 C1 ESR1 6q25.1
-q25.2
Promoter
5 prime
UTR
variant
SNP T/C BsrDI C ¼ 0.12 C ¼ 0.02 C ¼ 0.02 C/C
C/T
T/T
50-TTCTCCTTTCCCCTGTTCC-30
50-AGACCCCCAGTATTGCAG-
TG-30
rs3138774 C2 ” ” Promoter STR (TA)n – – – – S/S
S/L
L/L
5-GACGCATGATATACTTCACC-
30FAM
5-GCAGAATCAAATATCCA-
GATG-30
rs2234693 C3 ” ” Intron
promoter_
flanking_
region
SNP T/C PvuII C ¼ 0.45 C ¼ 0.42 C ¼ 0.43 C/C
C/T
T/T
50-GATATCCAGGGTTATGTGGCA-
30
50-AGGTGTTGCCTATTAT-
ATTAACCTTGA-30
rs9340799 C4 ” ” Intron
promoter_
flanking_
region
SNP A/G XbaI G ¼ 0.28 G ¼ 0.31 G ¼ 0.35 G/G
A/G
A/A
50-GATATCCAGGGTTATG-
TGGCA-30
50-AGGTGTTGCCTATTATATT-
AACCTTGA-30
SNP ¼ single-nucleotide polymorphism; STR ¼ short tandem repeat.
S
ex
M
ed
20
20
;-
:1e
11
A
nalysis
of
ER
a
in
G
ender
Incongruence
3
Figure 1. Adaptation of approximate positions of the analyzed polymorphisms in the ESR1 gene. Boxes indicate exons, and lines indicate
introns. Exon numbering is based on the primary transcripts as annotated in Ensembl (genome database project https://www.ensembl.org/
index.html). The dotted lines and unnumbered exons indicate introns and exons of alternative transcripts. The arrows indicate the
approximate positions of polymorphisms. Each polymorphism is labeled with the reference number (rs) assigned by NCBI (National Center
for Biotechnology Information).
4 Fernández et alThe exclusion criteria for all groups were: (1) presence of
neurological or psychiatric disorders, (2) presence of hormonal
disorders, (3) history of alcohol and/or drug abuse, (4) hospi-
talization for any reason in the 4 weeks before the evaluation, (5)
having a severe medical or psychiatric disorder, (6) chromosome
aneuploidy, inversions, and/or translocations.
To rule out the presence of psychiatric disorders and substance
abuse within all transgender participants, the Mini-International
Neuropsychiatric Interview28 was administered.
Applying the first 5 criteria, we excluded 39 trans women and
1 trans man. We also excluded individuals with chromosome
aneuploidy, inversions, and translocations (11 trans women and
8 trans men).29 The final sample was made up of an extremely
carefully chosen population of 273 trans women, 226 trans men,
252 cis women, and 285 cis men.
The study obtained the approval of the Ethics Committees of
the Clínic Hospital, the Regional Universitario Hospital of
Málaga and Universidad Nacional de Educación a Distancia
(Madrid). All participants in the study signed an informed
consent protocol beforehand.Molecular Analysis
Genomic DNA was extracted from EDTA blood samples
using the DNeasy Blood & Tissue Kit from Qiagen (Madrid,
Spain). The analyzed polymorphisms were 3 single nucleotide
polymorphisms (SNPs) C1 ¼ rs9478245, C3 ¼ rs2234693, and
C4 ¼ rs9340799; and one short tandem repeat polymorphism
(STR): C2 ¼ rs3138. According to the Ensembl database (www.
ensembl.org/), C1 and C2 polymorphisms are located in the
ESR1 promoter, while C3 and C4 are located in the promoter
flanking region (Table 1).
For SNPs (C1, C3, and C4), genotyping was performed by
the overnight digestion of the PCR products with the corre-
sponding digestion enzyme: BsrDI (Thermo Scientific, Madrid,
Spain), PvuII (BioLabs, Madrid, Spain) or XbaI (Roche, Madrid,
Spain), respectively. The digestion products were visualized in a
6% polyacrylamide electrophoresis gel (GE Healthcare, Madrid,
Spain). The genotypes resulting from BsrDI and PvuII digestionwere C/C, C/T, and T/T. And for XbaI were G/G, A/G, and A/
A (Table 1).
For STR polymorphism (C2), genotyping was performed by
automated capillary electrophoresis (3130 XL Genetic Analyzer,
Applied Biosystems, Madrid, Spain), and allele length was
determined by the GeneMapper-5 program (2012 Applied
Biosystems, Madrid, Spain).Statistical Analyses
The analyses were conducted by chromosomic sex, in 2 in-
dependent populations: individuals assigned as females at birth
and individuals assigned as males at birth, using SPSS 23.0 (IBM
Corp, Armonk, NY, USA), considering significant a P value
lower than 0.05.
For SNP polymorphisms (C1, C3, and C4), the allele and
genotype frequencies were analyzed by c2 test. The strength of
the associations with gender incongruence was measured by bi-
nary logistic regression, estimating the odds ratio (OR) for each
genotype combination.
For STR polymorphism (C2), the mean number of repeats
was analyzed by the ManneWhitney U test. Subsequently, it
was necessary to transform the C2 polymorphism into a
dichotomous variable, short (S) vs long (L) alleles, taking as a
cutoff the median obtained in the corresponding control group,
resulting in the genotypes S/S (short-short), L/L (long-long), and
S/L (short-long).
The 4 polymorphisms analyzed are located in the same
chromosome, very close to each other (Table 1; Figure 1), and
tend to be inherited together with a very high degree of corre-
lation called linkage disequilibrium being observed. In addition,
given that haplotypes may themselves be causal variants,30 we
were also interested in the simultaneous analysis of multiple loci
(haplotypes).
Measurement of linkage disequilibrium, designated as D0 and
r2, and subsequent measurement of haplotype frequencies were
performed using the free online software SNPStats (http://
bioinfo.iconcologia.net/SNPstats),31 using logistic regression
models to determine the strength of the associations. The falseSex Med 2020;-:1e11
Figure 2. The allele frequency of TA repeats for the C2 polymorphism in trans men and control cis women.
Analysis of ERa in Gender Incongruence 5positives were controlled with the Bonferroni correction. In all
analyses, a missing value for any response, polymorphism, or
covariate was cause for exclusion of that individual from the
analysis.RESULTS
The final sample was made up of a highly homogeneous
population of 273 trans women, 226 trans men, 252 cis women,
and 285 cis men, after applying inclusion and exclusion criteria
(39 trans women and 1 trans man were excluded), and excluding
individuals with chromosome aneuploidy, inversions, and
translocations (11 trans women and 8 trans men).
The polymorphisms were in Hardy-Weinberg equilibrium.
The C2 allele distribution was consistently bimodal in all groupsFigure 3. The allele frequency of TA repeats for the C
Sex Med 2020;-:1e11(Figures 2 and 3), with 2 peaks around 15 and 24 repeats. The
number of repeats ranged from 10 to 28. When the mean
number of repeats was analyzed by the ManneWhitney U test, a
difference was identified in the trans men population, having a
significantly shorter median (16 repeats) with respect to cis
women controls (18 repeats) (Z ¼ -2.035, P ¼ .042). The mean
number of repeats between trans women (17 repeats) and cis
men controls (18 repeats) was not significant (Z ¼ -0.610,
P ¼ .542).Analysis of the Allele and Genotype Frequencies by
c2
We found significant differences in the distribution of the
allele frequencies in the trans men vs cis women groups. We
found over transmission of the C2 allele S and the C4 allele A in2 polymorphism trans women and control cis men.
Table 2. C2 polymorphism association analysis with gender incongruence, in different models of inheritance
C2 association with transsexualism
Model Genotype
Cis
groups (%)
Trans
groups (%) OR (95% CI) P AIC BIC
Codominant S/S 22.4 31.8 1.00 (reference) – 572.3 588.8
S/L 52 49.4 0.67 (0.42e1.06) .07
L/L 25.7 18.8 0.52 (0.30e0.93) .023*
Dominant S/S 22.4 31.8 1.00 (reference) – 571.1 583.5
S/L-L/L 77.6 68.2 0.62 (0.40e0.96) .035*
Recessive S/S-S/L 74.3 81.2 1.00 (reference) – 573.2 585.5
L/L 25.7 18.8 0.68 (0.42e1.11) .12
Overdominant S/S-L/L 48 50.6 1.00 (reference) – 575.3 587.7
S/L 52 49.4 0.89 (0.60e1.33) .57
Log-additive — — — 0.72 (0.54e0.96) .023* 570.4 582.8
OR ¼ odds’ ratio; AIC ¼ Akaike’s information criterion; BIC ¼ Bayesian information criterion.
The risk for each genotype is compared with regards to the reference category (1.00 reference).
*Statistically significant (P  .05).
6 Fernández et althe trans men population (c2 ¼ 5.175; P ¼ .023 and
c2 ¼ 4.952; P ¼ .026, respectively).Association Analysis of Each Polymorphism With
Gender Incongruence
We found significant differences in the analysis of the strength
of the association with gender incongruence. The odds ratio
(OR) analysis for the C2 and C4 polymorphisms showed sig-
nificant differences for multiple patterns of inheritance (Tables 2
and 3). Genotypes S/S and S/L for C2 (Table 4) were genetic risk
factors (OR>1) for the somatically female population
[OR ¼ 2.62 (1.23-5.58); P ¼ .012 and OR ¼ 2.32 (1.32-4.06);
P ¼ .003, respectively]. With respect to the C4 polymorphism
(Table 5), the A/G genotype showed a genetic protective effectTable 3. C4 polymorphism association analysis with gender incongrue
C4 association with transsexualism
Model Genotype
Cis
women (%)
Trans
men (%)
Codominant A/A 31.7 55.2
A/G 53.3 32.8
G/G 15 11.9
Dominant A/A 31.7 55.2
A/G-G/G 68.3 44.8
Recessive A/A-A/G 85 88.1
G/G 15 11.9
Overdominant A/A-G/G 46.7 67.2
A/G 53.3 32.8
Log-additive — — —
OR ¼ odds’ ratio; AIC ¼ Akaike’s information criterion; BIC ¼ Bayesian inform
The risk for each genotype is compared with regards to the reference category
*Statistically significant (P  .05).
†Significant after the Bonferroni correction (P < .05/4 ¼ 0.0125).(OR<1) for the somatically female population [OR ¼ 0.35
(0.16-0.77); P ¼ .009] with respect to the A/A genotype.
Haplotype Analysis
TheT allele forC1was linked to the short (S) allele forC2, to the
T allele for C3 and to the A allele for C4 (haplotype 1: T-S-T-A)
(Table 6). However, the C allele for C1 was linked to the long (L)
allele for C2, to the C allele for C3 and to the G allele for C4
(haplotype 6: C-L-C-G) (Table 6). The more frequent haplotypes
were T-S-T-A (46.5%) and T-L-C-G (31.12%), while the
haplotypes C-S-T-A and C-L-C-A (Table 6) were not present.
Haplotype interaction analysis with covariate “sex” (Table 7)
showed that the haplotype 2: T-L-C-G represents a genetic
protective factor [OR ¼ 0.54 (0.35-0.83); P ¼ .005] for in-
dividuals assigned as females at birth, and it is overrepresented innce in cis women and trans men, in different models of inheritance
OR (95% CI) P AIC BIC
1.00 (reference) – 174.2 182.8
0.35 (0.16e0.77) .024*
0.46 (0.15e1.37) .169
1.00 (reference) – 172.5 178.1
0.38 (0.18e0.78) .007*,†
1.00 (reference) – 179.4 185.1
0.77 (0.28e2.14) .61
1.00 (reference) – 174.2 179.9
0.43 (0.21e0.88) .019*
0.57 (0.34e0.96) .03* 175 180.6
ation criterion.
(1.00 reference).
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Table 4. Interaction analysis of the C2 polymorphism with covariate “sex”
Sex within polymorphism C2
Cis groups (%) Trans groups (%) OR (95% CI) P
S/S XY 8.95 3.93 1.00 (reference) –
XX 5.90 6.77 2.62 (1.23e5.58) .012*,†
S/L XY 20.31 6.33 1.00 (reference) –
XX 14.19 10.26 2.32 (1.32e4.06) .003*,†
L/L XY 9.83 3.06 1.00 (reference) –
XX 7.21 3.28 1.46 (0.62e3.44) .393
Polymorphism C2 within sex
Cis groups (%) Trans groups (%) OR (95% CI) P
XY S/S 8.95 3.93 1.00 (reference) –
S/L 20.31 6.33 0.71 (0.36e1.42) .333
L/L 9.83 3.06 0.71 (0.31e1.60) .421
XX S/S 5.90 6.77 1.00 (reference) –
S/L 14.19 10.26 0.63 (0.33e1.19) .158
L/L 7.21 3.28 0.40 (0.18e0.88) .023*
The risk for each genotype is compared with regards to the reference category (1.00 reference).
*Statistically significant (P  .05).
†Significant after the Bonferroni correction (P < .05/4 ¼ 0.0125).
Analysis of ERa in Gender Incongruence 7the cis women population; while haplotype 3: T-L-C-A is
overrepresented in individuals assigned as females at birth
[OR ¼ 6.35 (1.35-29.96); P ¼ .019] vs individuals assigned as
males.DISCUSSION
We detected an association between the estrogen receptor a
gene ESR1 promoter and gender incongruence, in the trans men
population. Allele S (C2) and allele A (C4) were overrepresented
and significantly associated with gender incongruence in our
trans men population. Data from the C4 polymorphism
corroborate our previous publication.19,20Table 5. Interaction analysis of the C4 polymorphism with covariate
Sex within C4 polymorphism
Cis groups (%) Tran
A/A XY 52.27 37.2
XX 31.67 55.2
A/G XY 36.36 45.10
XX 53.33 32.8
G/G XY 11.36 17.6
XX 15 11.9
Polymorphism C4 within sex
Cis groups (%) Tran
XY A/A 52.27 37.2
A/G 36.36 45.10
G/G 11.36 17.6
XX A/A 31.67 55.2
A/G 53.33 32.8
G/G 15 11.9
The risk for each genotype is compared with regards to the reference category
*Statistically significant (P  .05).
†Significant after the Bonferroni correction (P < .05/4 ¼ 0.0125).
Sex Med 2020;-:1e11Furthermore, haplotypes are also associated with gender
incongruence. The haplotype 3: T-L-C-A was overrepresented in
the trans men population, while the haplotype 2: T-L-C-G was
overrepresented in cis populations. A theoretical analysis model
of the ESR1 promoter32 predicted that the C1 (C) and C2 (L)
minor alleles disrupted the transcription factor binding site for
the sex-determining region on the Y chromosome, Sry-related
HMG box-5 (SOX5), and the nerve growth factor-induced
protein C (NGF1C), respectively. In addition, the C allele for
C3 was predicted to remove the transcription factor binding sites
for activating enhancer binding protein 4 (AP-4) in the sense
strand, and the zinc finger protein ZNF238 (RP58) in the
antisense strand.32 Furthermore, C2 and C3 are located in a“sex”
s groups (%) OR (95% CI) P
5 1.00 (reference) –
2 2.36 (1.04e5.36) .039*
1.00 (reference) –
4 0.48 (0.21e1.11) .084
5 1.00 (reference) –
4 0.49 (0.12-2.11) .335
s groups (%) OR (95% CI) P
5 1.00 (reference) –
1.74 (0.72e4.20) .220
5 2.18 (0.62e7.61) .225
2 1.00 (reference) –
4 0.35 (0.16e0.77) .009*,†
4 0.46 (0.15e1.37) .17
(1.00 reference).
Table 6. Haplotype frequencies estimation
Haplotypes
Total Cis groups Trans groups Cumulative frequencyC1 C2 C3 C4
1 T S T A 0.465 0.444 0.492 0.465
2 T L C G 0.311 0.327 0.286 0.776
3 T L C A 0.086 0.070 0.099 0.862
4 T L T A 0.065 0.084 0.045 0.926
5 T S T G 0.020 0.015 0.024 0.947
6 C L C G 0.017 0.019 0.020 0.964
7 T S C A 0.016 0.024 0.008 0.980
8 T S C G 0.012 0.016 0.015 0.992
9 C S C G 0.008 0 0.011 1
10 C S T A 0 0 0 1
11 C L C A 0 0 0 1
8 Fernández et alhighly conserved region across species,32 and according to
Mooney, this enhances the possible implication of these 2
polymorphisms in the genetic basis (genetic vulnerability) of
transgender incongruence.33,34
Taking into account these considerations of the biological
importance of these polymorphisms,35 our results suggest thatTable 7. Haplotype and sex cross-classification interactions
Haplotypes
Frequency
Population w
C1 C2 C3 C4 OR (95% CI
1 T S T A 0.468 1.00 (refere
2 T L C G 0.306 1.01 (0.67e
3 T L C A 0.083 0.61 (0.22e
4 T L T A 0.066 0.35 (0.07e
5 T S T G 0.021 2.20 (0.39e
6 C L C G 0.019 –
7 T S C A 0.016 1.11 (0.13e
8 T S C G 0.014 –
rare 0.006 –
Haplotypes
Frequency
Population w
C1 C2 C3 C4 OR reference
1 T S T A 0.468 1.00 (refere
2 T L C G 0.306 1.00 (refere
3 T L C A 0.083 1.00 (refere
4 T L T A 0.066 1.00 (refere
5 T S T G 0.021 1.00 (refere
6 C L C G 0.019 1.00 (refere
7 T S C A 0.016 1.00 (refere
8 T S C G 0.014 1.00 (refere
rare 0.006 1.00 (refere
The risk for each haplotype is compared with regards to the reference categor
*Statistically significant (P  .05).
†Significant after the Bonferroni correction (P < .05/4 ¼ 0.0125).C2 might be a functional polymorphism influencing ESR1
expression regulation. However, these predictions need to be
confirmed by transcription factor binding experiments.
In addition, C3 and C4 polymorphisms are located in the first
intron of the ESR1 gene and have a demonstrated significant
effect on the level of protein synthesis.36 Herrington et al37 notedith XY karyotype Population with XX karyotype
P) P OR (95% CI)
nce) – 1.00 (reference) –
1.54) .966 0.54 (0.35e0.83) .005*,†
1.69) .347 2.53 (0.74e8.63) .139
1.83) .209 0.43 (0.15e1.21) .113
12.50) .379 – –
– 0.37 (0.07e1.82) .234
9.64) .931 – –
– 0.66 (0.07e6.49) .732
– – –
ith XY karyotype Population with XX karyotype
POR (95% CI)
nce) 1.52 (0.83e2.80) 0.178
nce) 0.81 (0.48e1.37) 0.439
nce) 6.35 (1.35e29.96) 0.019*
nce) 1.90 (0.33e11.02) 0.482
nce) – –
nce) – –
nce) – –
nce) – –
nce) – –
y (1.00 reference).
Sex Med 2020;-:1e11
Analysis of ERa in Gender Incongruence 9that the T/C variation for C3 results in a potential binding site
for transcription factors that could enhance in vitro transcription.
Thus, in some settings, the presence of the allele C (C3) might
amplify ESR1 transcription. Maruyama et al38 also detected a
small but significant enhancing activity that differed between
haplotypes: enhancer activity by allele G (C4) was higher than
the activity by allele A. Tangentially, pharmacogenetic studies on
osteoporosis have suggested that women with haplotype C(C3)-
G(C4) have a greater sensitivity to estrogen treatment than other
women.39
In summary, data from cell-based assays, gene expression
studies, and the fact that SNPs located in or near promoters have
functional implications in gene expression40,41 suggest that these
polymorphisms might be functional SNPs influencing ESR1
expression regulation. And thus, haplotypes T-L-C-A and T-L-
C-G could be involved in the genetic vulnerability of gender
incongruence in the trans men population.
In humans, the ESR1 and ESR2 genes encode the estrogen
receptors ERa and ERb, respectively, members of a family of
nuclear receptor transcription factors, which are activated by
estrogens. The 2 ERs exhibit different brain tissue distribution,
exhibit different estrogen-binding affinities,25 and also have
distinct transcriptional properties.42 Once bound by estrogens,
the ER undergoes a dimerization (homodimer ERa-a, homo-
dimer ERb-b, or heterodimer ERa-b), allowing the receptor to
interact with a greater or lesser affinity with specific DNA se-
quences located in or near promoter regions of target genes43,44
and thereby modulate a transcription cascade process.42,45 This
capacity to directly regulate protein synthesis contributes to the
potent and enduring effects of steroids on the developing
brain.22
Estrogen is an important regulator of brain differentiation, and
the ERs have a key function in sexual differentiation of brain and
behavior.46 In addition, ER a and b are found in both the
developing47 and adult human brain.48
If all these factors are taken into consideration, we could be
lead to suppose that ESR1 promoter sequence variations (hap-
lotypes) could modulate gene transcription, which, in turn, could
modify important characteristics of the ERa receptor, modifying
the receptor response to circulating estrogens during a prenatal
“critical period”, when the brain is sensitive to the organizational
effects of testosterone and its metabolite estradiol.22
And because steroid hormones are among the most powerful
and lasting signaling molecules in the body22 and, in addition, a
small variation in the receptor sensitivity could imply different
effects on different brain tissues,49 one might hypothesize that a
small variation in the ESR1 promoter sequence could implicate a
great change in the brain.
One of the limitations of our work is that the analyzed sample
is small and represents only a part of the trans population. As this
sample was obtained from the population that attended the
reference units requesting hormonal treatment, only a sample ofSex Med 2020;-:1e11trans people with dysphoria is analyzed in this paper. This makes
our sample very homogeneous, as required for genetic analysis,
but at the same time, it is only representative of a section of the
global trans reality.4
In conclusion, our results have shown that the promoter of the
ESR1 gene is a candidate for increasing the list of potential
“susceptibility” genes for gender incongruence. Furthermore, our
data continue to support the hypothesis that gender incongru-
ence is a multifactorial complex trait, involving intricate in-
teractions among steroids, steroids receptors, and multiple genes
and polymorphisms. Exploration of estrogen receptors by
methylation studies and also by microarray technology seems to
be an interesting future focus in the study of sexual differentia-
tion of the brain.ACKNOWLEDGMENTS
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